Alternating R-CHOP and R-cytarabine is a safe and effective
regimen for transplant-ineligible patients with a newly
diagnosed mantle cell lymphoma

J 2018

Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma

KLENER, Pavel, Eva FRONKOVA, David BELADA, Kristina FORSTEROVA, Robert PYTLIK et. al.

Basic information

Original name

Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma

Authors

KLENER, Pavel (203 Czech Republic, guarantor), Eva FRONKOVA (203 Czech Republic), David BELADA (203 Czech Republic), Kristina FORSTEROVA (203 Czech Republic), Robert PYTLIK (203 Czech Republic), Marketa KALINOVA (203 Czech Republic), Martin SIMKOVIC (203 Czech Republic), David ŠÁLEK (203 Czech Republic, belonging to the institution), Heidi MOCIKOVA (203 Czech Republic), Vít PROCHAZKA (203 Czech Republic), Petra BLAHOVCOVA, Andrea JANÍKOVÁ (203 Czech Republic, belonging to the institution), Jana MARKOVA (203 Czech Republic), Ales OBR (203 Czech Republic), Adela BERKOVA (203 Czech Republic), Jozef KUBINYI (203 Czech Republic), Martina VASKOVA (203 Czech Republic), Ester MEJSTRIKOVA (203 Czech Republic), Vít CAMPR (203 Czech Republic), Radek JAKSA (203 Czech Republic), Roman KODET (203 Czech Republic), Kyra MICHALOVA (203 Czech Republic), Jan TRKA (203 Czech Republic) and Marek TRNENY (203 Czech Republic)

Edition

Hematological Oncology, MALDEN, USA, WILEY-BLACKWELL, 2018, 0278-0232

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 3.439

RIV identification code

RIV/00216224:14110/18:00104075

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1002/hon.2483

UT WoS

000425633300016

Keywords in English

elderly patients; high-dose cytarabine; mantle cell lymphoma; PET-CT; rituximab maintenance

Abstract

V originále

Implementation of cytarabine into induction therapy became standard of care for younger patients with mantle cell lymphoma (MCL). On the basis of its beneficial impact, many centers incorporated cytarabine at lower doses also into first-line treatments of elderly patients. We conducted a multicenter observational study that prospectively analyzed safety and efficacy of alternating 3+3cycles of R-CHOP and R-cytarabine for newly diagnosed transplant-ineligible MCL patients. A total of 73 patients were enrolled with median age 70years. Most patients had intermediate (39.7%) and high-risk (50.7%) disease according to MCL international prognostic index. Rituximab maintenance was initiated in 58 patients. Overall response rate reached 89% by positron emission tomography-computed tomography, including 75.3% complete remissions. Two patients (2.7%) did not complete the induction therapy because of toxicity. Three patients (4.1%) were considered nonresponders, which led to therapy change before completion of induction. Estimated progression-free survival and overall survival were 51.3% and 68.6% at 4years, respectively. Mantle cell lymphoma international prognostic index, bulky disease ( 5cm), and achievement of positron emission tomography-negativity independently correlated with progression-free survival. Grade 3 to 4 hematologic and nonhematologic toxicity was documented in 48% and 20.5% patients, respectively. Alternation of R-CHOP and R-cytarabine represents feasible and very effective regimen for elderly/comorbid MCL patients. This study was registered at GovTrial () NCT03054883.

Citovat

KLENER, Pavel, Eva FRONKOVA, David BELADA, Kristina FORSTEROVA, Robert PYTLIK, Marketa KALINOVA, Martin SIMKOVIC, David ŠÁLEK, Heidi MOCIKOVA, Vít PROCHAZKA, Petra BLAHOVCOVA, Andrea JANÍKOVÁ, Jana MARKOVA, Ales OBR, Adela BERKOVA, Jozef KUBINYI, Martina VASKOVA, Ester MEJSTRIKOVA, Vít CAMPR, Radek JAKSA, Roman KODET, Kyra MICHALOVA, Jan TRKA and Marek TRNENY. Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma. Hematological Oncology. MALDEN, USA: WILEY-BLACKWELL, 2018, vol. 36, No 1, p. 110-115. ISSN 0278-0232. Available from: https://dx.doi.org/10.1002/hon.2483.

@article{1450957,
   author = {Klener, Pavel and Fronkova, Eva and Belada, David and Forsterova, Kristina and Pytlik, Robert and Kalinova, Marketa and Simkovic, Martin and Šálek, David and Mocikova, Heidi and Prochazka, Vít and Blahovcova, Petra and Janíková, Andrea and Markova, Jana and Obr, Ales and Berkova, Adela and Kubinyi, Jozef and Vaskova, Martina and Mejstrikova, Ester and Campr, Vít and Jaksa, Radek and Kodet, Roman and Michalova, Kyra and Trka, Jan and Trneny, Marek},
   article_location = {MALDEN, USA},
   article_number = {1},
   doi = {http://dx.doi.org/10.1002/hon.2483},
   keywords = {elderly patients; high-dose cytarabine; mantle cell lymphoma; PET-CT; rituximab maintenance},
   language = {eng},
   issn = {0278-0232},
   journal = {Hematological Oncology},
   title = {Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma},
   volume = {36},
   year = {2018}
}

TY  - JOUR
ID  - 1450957
AU  - Klener, Pavel - Fronkova, Eva - Belada, David - Forsterova, Kristina - Pytlik, Robert - Kalinova, Marketa - Simkovic, Martin - Šálek, David - Mocikova, Heidi - Prochazka, Vít - Blahovcova, Petra - Janíková, Andrea - Markova, Jana - Obr, Ales - Berkova, Adela - Kubinyi, Jozef - Vaskova, Martina - Mejstrikova, Ester - Campr, Vít - Jaksa, Radek - Kodet, Roman - Michalova, Kyra - Trka, Jan - Trneny, Marek
PY  - 2018
TI  - Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma
JF  - Hematological Oncology
VL  - 36
IS  - 1
SP  - 110-115
EP  - 110-115
PB  - WILEY-BLACKWELL
SN  - 02780232
KW  - elderly patients
KW  - high-dose cytarabine
KW  - mantle cell lymphoma
KW  - PET-CT
KW  - rituximab maintenance
N2  - Implementation of cytarabine into induction therapy became standard of care for younger patients with mantle cell lymphoma (MCL). On the basis of its beneficial impact, many centers incorporated cytarabine at lower doses also into first-line treatments of elderly patients. We conducted a multicenter observational study that prospectively analyzed safety and efficacy of alternating 3+3cycles of R-CHOP and R-cytarabine for newly diagnosed transplant-ineligible MCL patients. A total of 73 patients were enrolled with median age 70years. Most patients had intermediate (39.7%) and high-risk (50.7%) disease according to MCL international prognostic index. Rituximab maintenance was initiated in 58 patients. Overall response rate reached 89% by positron emission tomography-computed tomography, including 75.3% complete remissions. Two patients (2.7%) did not complete the induction therapy because of toxicity. Three patients (4.1%) were considered nonresponders, which led to therapy change before completion of induction. Estimated progression-free survival and overall survival were 51.3% and 68.6% at 4years, respectively. Mantle cell lymphoma international prognostic index, bulky disease ( 5cm), and achievement of positron emission tomography-negativity independently correlated with progression-free survival. Grade 3 to 4 hematologic and nonhematologic toxicity was documented in 48% and 20.5% patients, respectively. Alternation of R-CHOP and R-cytarabine represents feasible and very effective regimen for elderly/comorbid MCL patients. This study was registered at GovTrial () NCT03054883.
ER  -

KLENER, Pavel, Eva FRONKOVA, David BELADA, Kristina FORSTEROVA, Robert PYTLIK, Marketa KALINOVA, Martin SIMKOVIC, David ŠÁLEK, Heidi MOCIKOVA, Vít PROCHAZKA, Petra BLAHOVCOVA, Andrea JANÍKOVÁ, Jana MARKOVA, Ales OBR, Adela BERKOVA, Jozef KUBINYI, Martina VASKOVA, Ester MEJSTRIKOVA, Vít CAMPR, Radek JAKSA, Roman KODET, Kyra MICHALOVA, Jan TRKA and Marek TRNENY. Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma. \textit{Hematological Oncology}. MALDEN, USA: WILEY-BLACKWELL, 2018, vol.~36, No~1, p.~110-115. ISSN~0278-0232. Available from: https://dx.doi.org/10.1002/hon.2483.

Detailed Information on Publication Record